The biotechnology industry is one of the favorite industries for investing in up-and-coming companies. A lot of them offer promise, but few end up making it to the finish line. In this article, I will discuss why Celgene has been so strong and why it will continue to do so in the future. Before we get to that, let's go over an example of how the biotechnology industry can more »
Typically, it doesn't take a lot for a stock to trade with gains of more than 5% in a session; it can be caused by an analyst's remarks, sometimes it's caused by earnings, or maybe it’s just a technical rally. Sometimes the moves are warranted and other times they are not. Therefore, I am looking at several moves higher to determine if the stocks are presenting more »
For the most part, there was very little movement in the biotechnology industry on Friday. It was a slow day as almost every stock trading in a range of 2% lower to 2% higher. However, there were a few that saw major movement, and in this article I am looking at those select few.
Sarepta Therapeutics (NASDAQ: SRPT)
I bought shares of Sarepta back in November at $25.50, and more »
After a week of trending lower, Celsion (NASDAQ: CLSN) rallied with gains of more than 10.50% following the announcement of a partnership in China. Under the terms of the partnership, Celsion will receive upfront cash and incentives up to $100 million. This created a sense of relief to current investors ahead of company changing data. However, investors shouldn’t use this news as a guaranteed proof of success, and more »
Healthcare stocks are always the most volatile in the market, regardless of the market’s overall direction. On Tuesday we saw mass movement in this space from five high-profile stocks. Therefore, I am looking at this movement, determining what it means, and suggesting how to play it.
Biotechnology can be one of the most volatile industries to be invested in. A lot of the time, investors can own shares in various companies and not even know there is an event coming up. This article will serve to inform investors of 6 biotechnology stocks that have upcoming catalysts in 2013. These catalysts are likely to have a significant impact upon each company.
1) Celsion Corporation (NASDAQ: CLSN)
Celsion more »
Our database of insider trading filings allows us to pick out companies that have seen recent insider purchases- studies show that on average stocks bought by insiders tend to beat the market- and take a brief look at the company to see if it might be worth investigating further. It’s impossible to buy every stock that insiders are buying, but it’s certainly possible to use insider buying as more »
Never before a title of a mythical film was so well suited to three biotech and biopharma companies. The year 2012 is nearing completion and it is time to recap the movements produced in various biotech, biopharma and pharma companies. But three companies are about to end the year far from how they started it. We are going to start with "The Good."
This company is conducting one more »
During this year, investors in biotech, pharma and biopharma stocks have seen how several companies have multiplied their value. Some of these companies are Arena Pharmaceuticals (NASDAQ: ARNA) , Celsion Corporation (NASDAQ: CLSN) or Sarepta Therapeutics (NASDAQ: SRPT). Their strong volatility makes their prices fluctuate in excess. This sector usually provides a possible high gain, but this implies having to take a high risk. Finding biopharmaceutical companies that are undervalued can more »
As we head to the end of the year, let’s take a look at some stocks in the biopharma sector that have managed to do extremely well in 2012. I’ll also take a look at what their outlook is for next year.
Arena Pharmaceuticals (NASDAQ: ARNA) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral drugs that target G protein-coupled receptors (GPCRs) in more »
Celsion Corporation (NASDAQ: CLSN) is an innovative oncology drug development company singularly focused on improving treatment for those suffering from highly difficult to treat forms of cancer. It is working to develop and market more efficient, effective, and targeted chemotherapeutic treatments based on its unique heat-activated liposomal technology. Celsion has seen some intense insider activity in recent days, which is why I want to take a look at the company more »
This is the question I ask to myself every time I try to find insider activity in Acadia Pharmaceuticals (NASDAQ: ACAD). This biopharmaceutical company, which focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders, has recently announced that it redesigned an ongoing late-stage study on its experimental anti-psychotic drug for Parkinson's Disease patients, and that it plans to conduct an more »
Purchasing small biotech companies can be compared to purchasing a lottery ticket. If their blockbuster drug gets approved by the FDA, then the stock doubles in a day. If the drug does not get approved, the company putters along, reevaluating their position. That is why I strongly believe that long-term investors should not focus on small biotechnology companies, yet every once and a while, investors can buy a lottery ticket more »